Tetraphase Pharmaceuticals
Mar 6, 2017

Tetraphase Pharmaceuticals to Present at the 29th Annual ROTH Conference

WATERTOWN, Mass., March 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 29th Annual ROTH Conference on Monday, March 13, 2017 at 8:00 a.m. Pacific Time at the Ritz Carlton Hotel in Dana Point, CA.

A live audio webcast of the ROTH presentation will be available on the company's website at http://ir.tphase.com/events.cfm. An archived presentation will be available for 30 days.

About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information. 

Investor Contacts:

Tetraphase Pharmaceuticals

Teri Dahlman

617-600-7040

tdahlman@tphase.com



Argot Partners

Maeve Conneighton

206-899-4940

maeve@argotpartners.com



Media Contact:

Sam Brown Inc.

Mike Beyer

312-961-2502

mikebeyer@sambrown.com

Primary Logo

Source: Tetraphase Pharmaceuticals

News Provided by Acquire Media